Safety of Mesenchymal Stem Cell Extracellular Vesicles (BM-MSC-EVs) for the Treatment of Burn Wounds
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Mesenchymal stem cells (MSCs) have been used in a variety of clinical applications to repair
and regenerate damaged tissue. Previous research has demonstrated the safety and efficacy of
delivering bone marrow cells including MSCs to chronic wounds with significant improvement in
healing and scarring. Application of mesenchymal stem cell (MSC) therapy to severe burn
wounds represents an opportunity for improved outcomes where alternate therapies are limited
and often ineffective.
In this protocol, 2nd degree burn wounds will receive direct application of EVs derived from
bone marrow MSCs. We have observed success with this type of approach in the past using bone
marrow stem cells including MSCs. We have evidence that EVs derived from MSCs are responsible
for many of the healing effects produced by MSCs and may be a safer, more reliable
alternative to allogeneic cell therapy. This protocol is designed to develop a safe and ideal
method of administering bone marrow cell Extracellular Vesicles to wounds.
Phase:
Phase 1
Details
Lead Sponsor:
Aegle Therapeutics
Collaborator:
Congressionally Directed Medical Research Programs